University of California, San Francisco |
Webinar Date: Wednesday, August 25, 2021 Please join and bring your clinical questions for this interactive office hour session hosted by the National Clinician Consultation Center (NCCC) and the Health Resources & Services Administration’s Bureau of Primary Health Care (HRSA BPHC). The interplay between substance use, HIV, and hepatitis C virus (HCV) present unique challenges and […]
Archive | Cases of Interest
Highlighted here are specific cases that represent current questions from our clinician consultations.
Webinar: Management of Stimulant Use Disorder
Webinar Date: Tuesday, April 27, 2021 Please join the National Clinician Consultation Center (NCCC) in partnership with the Health Resources & Services Administration’s Bureau of Primary Health Care for this webinar, developed for health center clinicians. The misuse of stimulants, comprised of methamphetamine, cocaine, and other amphetamines, is a growing public health crisis across the United […]
Webinar: Buprenorphine for Adults with Substance Use Disorder and Co-Occurring Pain
Webinar Date: Wednesday, February 3, 2021 Please join the National Clinician Consultation Center (NCCC) in partnership with the Health Resources and Services Administration’s Bureau of Primary Health Care for this webinar, developed for health center clinicians. Pain and substance use disorders (SUD) co-occur frequently, and access to medical treatment for both has been appreciably disrupted by […]
Webinar: Management of Alcohol Use Disorder
Webinar Date: Thursday, October 22, 2020 Please join the National Clinician Consultation Center (NCCC) in partnership with the Health Resources and Services Administration’s Bureau of Primary Health Care for this interactive webinar for Health Center clinicians. Unhealthy alcohol use remains a growing public health issue in the United States, contributing significantly to the global burden of […]
Webinar: HIV Pre-Exposure Prophylaxis (PrEP) for Patients with Substance Use Disorders
Webinar Date: May 27, 2020 Please join the National Clinician Consultation Center in partnership with the Health Resources and Services Administration’s Bureau of Primary Health Care for this interactive webinar for Health Center clinicians. PrEP is a highly effective biomedical intervention that prevents HIV. Despite the established association between HIV risk and substance use, PrEP […]
Information about COVID-19 for Clinicians
Because of the rapidly-changing understanding of COVID-19, here are some of the key links to guidances for clinicians: Interim Guidance for COVID-19 and Persons with HIV Open Link | From AIDSinfo (DHHS) HRSA HIV/AIDS Bureau (HAB) Frequently Asked Questions Open Link | From Health Resources & Services Administration (HRSA) Information for Healthcare Professionals Open Link […]
Webinar: Pharmacotherapy for Depression and Anxiety in Patients with Opioid Use Disorder
Webinar Date: February 19, 2020 The National Clinician Consultation Center in partnership with the Health Resources and Services Administration’s Bureau of Primary Health Care present this Technical Assistance Office Hour for Health Center clinicians. Mood and anxiety symptoms place a heavy burden on patients entering into treatment for opioid use disorder (OUD). Medications such as […]
CCC Update to FDA Notice: Dolutegravir and Post-Exposure Prophylaxis (PEP)
**PLEASE NOTE: This statement is now outdated. We will provide updates when additional data is available. In the meantime, please reference the HHS Perinatal Guidelines for more information on dolutegravir in pregnancy and pre-conception: https://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0** On May 30, 2018 the HHS Antiretroviral Guidelines Panels issued recommendations on the use of dolutegravir for treatment of adults and […]
CCC Response to FDA Notice: Dolutegravir and Post-Exposure Prophylaxis (PEP)
The U.S. Food and Drug Administration (FDA) alerted the public on 5/18/18 that serious cases of neural tube birth defects have been reported in babies born to women living with HIV who were treated with dolutegravir at the time of becoming pregnant or early in the first trimester (https://fda.gov/Drugs/DrugSafety/ucm608112.htm). Until more information is available, we […]
Case of the Month: Concurrent Heroin and Methamphetamine Use Disorders
Case Summary A provider called the Substance Use Warmline about a 32 year old male with history of major depressive disorder, newly enrolled in primary care, and with unknown status for HIV, HCV and HBV. The patient initially presented with a 6-month history of new heroin and methamphetamine use, and also reported a history of […]